Study on the Use of a Herbal Supplement (DiaB Max ) Along with Regular Treatment in People with Type 2 Diabetes to improve blood sugar level.

Effectiveness of Advanced Supercritical Fluid Extraction based herbal drug (DiaB Max TM) as an adjunctive therapy in the management of Type 2 Diabetic Patients: A Randomized Controlled, Double-Blind Clinical Trial. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/07/090572

Enrollment

Registered

2025-07-09

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Type 2 Diabetes Mellitus patients above 18 years of age. Patients receiving antihyperglycemic medication before randomization and HbA1c between 6.5% to 10% at randomization. Patients willing to give informed consent.

Exclusion criteria

Exclusion criteria: Type 1 Diabetes or uncontrolled T2DM with HbA1c more than 10 %. Patients with known hypersensitivity to any herbal component. Pregnant or lactating women. Patients with history of severe liver or kidney disease.

Design outcomes

Primary

Measure	Time frame
DiaB Max a SCFE-based novel herbal formulation may provide improvement in insulin sensitivity.Timepoint: DiaB Max a SCFE-based novel herbal formulation may provide improvement in insulin sensitivity.	—

Secondary

Measure	Time frame
DiaB Max a SCFE-based novel herbal formulation may result in reduction of HbA1c, FBS, PPBS levelsTimepoint: 90 days	—

Countries

India

Contacts

Public ContactDr V Sriramavaratharajan

SRM Institute of Science and Technology

vijaypractice@yahoo.com9003400450

Outcome results